

## Xyrem<sup>®</sup> (sodium oxybate) – First-time authorized brand alternative

- On January 3, 2023, [Hikma launched](#) an authorized brand alternative (ABA) of Jazz's [Xyrem \(sodium oxybate\)](#) oral solution.
  - Hikma will have 180 days of marketing exclusivity for its ABA product in the U.S.
- Xyrem is approved for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
- Xyrem carries a boxed warning for central nervous system depression, and abuse and misuse.
- Jazz reported net sales for Xyrem of \$1.3 billion in 2021.